What did @shawnwells actually say?
Wells made two distinct arguments in this clip. First, the science-adjacent one: GHK-Cu is a naturally occurring peptide with real biological activity relevant to skin and hair. Second, the conspiracy one: drug companies "hate" peptides because they can't be patented, and that's why compound pharmacies are being targeted and peptides "are being banned." He also claimed people using BPC-157 have "avoided surgeries" with results he called "pretty dramatic."
These two arguments deserve to be separated, because one has some grounding in biology and one is a narrative that requires real scrutiny. The caption adds a specific claim about GHK-Cu blood levels dropping from 200 ng/mL at age 20 to 8 ng/mL by age 60, which is a number worth tracking down.
Does the science back this up?
Partially, but not cleanly. GHK-Cu is real, studied, and genuinely interesting. The "can't be patented, so pharma ignores it" framing, however, is a significant oversimplification that shades into misinformation.
GHK (glycyl-L-histidyl-L-lysine) copper complex does occur naturally in human plasma, saliva, and urine. Loren Pickart, who has published on GHK-Cu since the 1970s, documented that plasma levels do decline with age. A 2015 review by Pickart and Margolina in the journal Cosmetics cited declining GHK plasma concentrations as a driver of age-related changes in tissue repair capacity. The specific numbers in the caption (200 ng/mL to 8 ng/mL) appear to circulate widely online but the primary sourcing is difficult to independently verify in peer-reviewed literature. That's a problem.
On the pharma-suppression argument: the FDA's actions against certain compounded peptides, including BPC-157, reflect concerns about drug approval pathways and safety data gaps, not a coordinated effort to protect profits. The FDA placed BPC-157 on its "list of drug substances that cannot be compounded" in 2022 citing insufficient clinical evidence, not because it threatens a competitor product.
What did they get wrong (or right)?
Credit where it's due: GHK-Cu does have a legitimate research base. Studies including Pickart et al. (2015, Cosmetics) and work published in Archives of Dermatological Research have shown GHK-Cu influences wound healing, collagen synthesis, and anti-inflammatory signaling in cell and animal models. Calling peptides "signals" that tell the body to do things is actually a decent lay description of how they work mechanistically.
What Wells got wrong is more consequential. The claim that BPC-157 helps people "avoid surgeries" is anecdotal and extrapolates from rodent studies. There are no completed randomized controlled trials in humans for BPC-157 as of this writing. Presenting outcomes from user testimonials as evidence that a peptide works is the kind of reasoning that gets people hurt, or at minimum, keeps them from pursuing treatments that do have evidence behind them.
The conspiracy framing is also factually soft. Drug companies do fund research selectively, and patent economics do shape what gets studied. That's true and documented. But the leap to "Big Pharma doesn't want you to have them" implies an organized suppression campaign. That's not what regulatory records show. The FDA's compound pharmacy crackdown has a documented paper trail tied to DSHEA and drug approval law, not a secret industry agenda.
What should you actually know?
GHK-Cu is one of the more studied peptides in cosmetic and wound-healing research, which means something in a field full of undersupported compounds. But "more studied" doesn't mean "clinically proven for anti-aging or hair loss in humans." Most GHK-Cu research is in vitro or animal-based. Human trials are limited in size and scope.
If you're seeing GHK-Cu in a skincare product or hearing about it from a telehealth provider, asking for the specific evidence behind the specific application matters. Topical GHK-Cu in cosmetics has a different evidence profile than injected peptide therapy. Conflating them is common in wellness content and it shouldn't be.
The regulatory environment around compounded peptides is genuinely complicated right now. The FDA's actions affect patient access in real ways, and reasonable people disagree about whether those actions are proportionate. But framing that debate as pharma corruption, rather than a dispute about evidence standards and drug law, doesn't help anyone make better decisions about their health.